{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:15Z","timestamp":1787008635283,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oral and intravenous (IV) omadacycline formulations are approved in the United States for treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults. Oral omadacycline bioavailability is 34.5%; similar exposures are obtained following 300 mg oral and 100 mg IV doses. Oral administration should be in a fasted state, with dairy products, antacids, or multivitamins avoided for \u22654 hours after dosing. Low protein binding (21%), large volume of distribution (190 L), low systemic clearance (10 L\/hour), and long elimination half-life (16\u201317 hours) support once-daily dosing. Omadacycline is excreted unchanged in feces (81.1%) and urine (14.4%), with low potential for drug\u2013drug interactions. Dose adjustments are unnecessary for age, sex, and renal or hepatic impairment. Pharmacokinetic\u2013pharmacodynamic studies identify fAUC0\u201324\/MIC ratio as the parameter that correlates with in vivo efficacy. Systemic exposure of omadacycline in epithelial lining fluid is greater than\/equal to plasma concentrations in healthy adults.<\/jats:p>","DOI":"10.1093\/cid\/ciz309","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T16:31:42Z","timestamp":1554913902000},"page":"S16-S22","source":"Crossref","is-referenced-by-count":56,"title":["Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline"],"prefix":"10.1093","volume":"69","author":[{"given":"Keith A","family":"Rodvold","sequence":"first","affiliation":[{"name":"University of Illinois at Chicago, Colleges of Pharmacy and Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath P","family":"Pai","sequence":"additional","affiliation":[{"name":"University of Michigan, College of Pharmacy, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2019080101103003900_CIT0001","volume-title":"NUZYRA (omadacycline) prescribing information"},{"key":"2019080101103003900_CIT0002","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","article-title":"Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic","volume":"24","author":"Tanaka","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"2019080101103003900_CIT0003","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol"},{"key":"2019080101103003900_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2017.06.002","article-title":"Antibacterial drug development program successes and failures: a pharmacometric explanation","volume":"36","author":"Ambrose","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"2019080101103003900_CIT0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10928-017-9506-4","article-title":"What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles","volume":"44","author":"Bush","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2019080101103003900_CIT0006","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1128\/AAC.01393-16","article-title":"Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects","volume":"60","author":"Sun","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101103003900_CIT0007","doi-asserted-by":"crossref","first-page":"e01487-17","DOI":"10.1128\/AAC.01487-17","article-title":"Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens","volume":"62","author":"Bundrant","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101103003900_CIT0008","doi-asserted-by":"crossref","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101103003900_CIT0009","doi-asserted-by":"crossref","first-page":"e01784-16","DOI":"10.1128\/AAC.01784-16","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101103003900_CIT0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline","volume":"47","author":"Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"2019080101103003900_CIT0011","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jcph.814","article-title":"Effect of food on the bioavailability of omadacycline in healthy participants","volume":"57","author":"Tzanis","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2019080101103003900_CIT0012","article-title":"Population pharmacokinetics of omadacycline following intravenous or oral administration to phase I subjects [abstract P1320]","volume-title":"Program and abstracts of the 26th European Congress of Clinical Microbiology and Infectious Diseases","author":"van Wart","year":"2016"},{"key":"2019080101103003900_CIT0013","article-title":"Single and multiple dose pharmacokinetics and tolerability of intravenous omadacycline in healthy volunteers [abstract P1319]","volume-title":"Program and abstracts of the 26th European Congress of Clinical Microbiology and Infectious Diseases","author":"Tanaka","year":"2016"},{"key":"2019080101103003900_CIT0014","doi-asserted-by":"crossref","first-page":"e02057-17","DOI":"10.1128\/AAC.02057-17","article-title":"Pharmacokinetics and safety of omadacycline in subjects with impaired renal function","volume":"62","author":"Berg","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101103003900_CIT0015","article-title":"Pharmacokinetics and safety of omadacycline in patients with uncomplicated urinary tract infections [abstract 200]","volume-title":"Program and abstracts of ASM Microbe","author":"Overcash","year":"2017"},{"key":"2019080101103003900_CIT0016","article-title":"In vitro protein binding with omadacycline, a first in class aminomethylcycline antibiotic [abstract 518]","volume-title":"Program and abstracts of ASM Microbe","author":"Villano","year":"2016"},{"key":"2019080101103003900_CIT0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/9781420017137.013","article-title":"Pharmacokinetics and pharmacodynamics of tetracyclines","volume-title":"Pharmacodynamics in theory and clinical practice","author":"Andes","year":"2007","edition":"2"},{"key":"2019080101103003900_CIT0018","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2019080101103003900_CIT0019","article-title":"A pharmacokinetic comparison of omadacycline and tigecycline epithelial lining fluid penetration [abstract 1850]","volume-title":"Program and abstracts of IDWeek","author":"Lakota","year":"2017"},{"key":"2019080101103003900_CIT0020","article-title":"Pharmacokinetics of omadacycline (PTK0796) in subjects with hepatic impairment [abstract 1282]","volume-title":"Program and abstracts of the 52nd Annual Interscience Conference of Antimicrobial Agents and Chemotherapy","author":"Ting","year":"2012"},{"key":"2019080101103003900_CIT0021","article-title":"Effect of age and gender on the pharmacokinetics of oral and IV omadacycline, a new class of aminomethylcyclines [abstract 1318]","volume-title":"Program and abstracts of the 26th European Congress of Clinical Microbiology and Infectious Diseases","author":"Tanaka","year":"2016"},{"key":"2019080101103003900_CIT0022","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/jac\/dkn242","article-title":"Tigecycline pharmacokinetic\/pharmacodynamic update","volume":"62","author":"MacGowan","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2019080101103003900_CIT0023","article-title":"Post-antibiotic effect of omadacycline against target pathogens [abstract 512]","volume-title":"Program and abstracts of the ASM Microbe","author":"Hinshaw","year":"2016"},{"key":"2019080101103003900_CIT0024","doi-asserted-by":"crossref","first-page":"e02368-16","DOI":"10.1128\/AAC.02368-16","article-title":"In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101103003900_CIT0025","article-title":"In vivo pharmacodynamics of MK-2764\/PTK 0796 against Gram-positive and Gram-negative bacteria in the thighs of neutropenic and normal mice [abstract 1875]","volume-title":"Program and abstracts of the 46th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy","author":"Craig","year":"2006"},{"key":"2019080101103003900_CIT0026","article-title":"In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the murine thigh infection model [abstract 1531]","volume-title":"Program and abstract of IDWeek","author":"Lepak","year":"2017"},{"key":"2019080101103003900_CIT0027","article-title":"Pharmacokinetic\/pharmacodynamics profile of MK-2764\/PTK 0796 against S. pneumoniae in a murine pneumonia model [abstract 1888]","volume-title":"Program and abstracts of the 46th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy","author":"Tessier","year":"2006"},{"key":"2019080101103003900_CIT0028","article-title":"In vitro activity of omadacycline (PTK796) in broth, broth plus lung surfactant or human serum [abstract P1141]","volume-title":"Program and abstracts of the 21st European Congress of Clinical Microbiology and Infectious Diseases","author":"Macone","year":"2011"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/Supplement_1\/S16\/29021863\/ciz309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T14:31:08Z","timestamp":1663252268000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/Supplement_1\/S16\/5541771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":28,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz309","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,15]]},"published":{"date-parts":[[2019,8,1]]}}}